• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Correlates of the "No-Reflow" or "Slow-Flow" Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention.接受直接经皮冠状动脉介入治疗患者中“无复流”或“慢血流”现象的相关因素
J Tehran Heart Cent. 2018 Jul;13(3):108-114.
2
Predictive value of admission red cell distribution width-platelet ratio for no-reflow phenomenon in acute ST segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.入院时红细胞分布宽度-血小板比值对接受直接经皮冠状动脉介入治疗的急性ST段抬高型心肌梗死患者无复流现象的预测价值
Cardiol J. 2016;23(1):84-92. doi: 10.5603/CJ.a2015.0070. Epub 2015 Oct 27.
3
Clinical and procedural predictors of no-reflow in patients with acute myocardial infarction after primary percutaneous coronary intervention.直接经皮冠状动脉介入治疗急性心肌梗死后无复流的临床和操作预测因素。
World J Emerg Med. 2014;5(2):96-102. doi: 10.5847/wjem.j.issn.1920-8642.2014.02.003.
4
Plasma apelin-12 levels may predict in-hospital major adverse cardiac events in ST-elevation myocardial infarction and the relationship between apelin-12 and the neutrophil/lymphocyte ratio in patients undergoing primary coronary intervention.血浆apelin-12水平可能预测ST段抬高型心肌梗死患者住院期间的主要不良心脏事件以及接受直接冠状动脉介入治疗患者中apelin-12与中性粒细胞/淋巴细胞比值之间的关系。
Perfusion. 2017 Apr;32(3):206-213. doi: 10.1177/0267659116676335. Epub 2016 Oct 22.
5
Quantification Of Thrombus Burden As An Independent Predictor Of Intra-Procedural No-Reflow In Patients With St-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Revascularization.在接受直接经皮冠状动脉血运重建术的 ST 段抬高型心肌梗死患者中,血栓负荷的定量分析作为术中无复流的独立预测因子。
J Ayub Med Coll Abbottabad. 2022 Apr-Jun;34(2):288-294. doi: 10.55519/JAMC-02-9698.
6
The relationship between serum rheumatoid factor level and no-reflow phenomenon in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.急性ST段抬高型心肌梗死患者接受直接经皮冠状动脉介入治疗时血清类风湿因子水平与无复流现象的关系
J Clin Lab Anal. 2018 Nov;32(9):e22598. doi: 10.1002/jcla.22598. Epub 2018 Jun 26.
7
Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon.急性心肌梗死中梗死相关动脉的血管造影形态学特征及及时再灌注:慢血流和无再流现象的预测因素
Chest. 2002 Oct;122(4):1322-32. doi: 10.1378/chest.122.4.1322.
8
Evaluation of the Clinical and Procedural Predictive Factors of no-Reflow Phenomenon Following Primary Percutaneous Coronary Intervention.直接经皮冠状动脉介入治疗后无复流现象的临床及操作预测因素评估
Res Cardiovasc Med. 2015 May 23;4(2):e25414. doi: 10.5812/cardiovascmed.4(2)2015.25414. eCollection 2015 May.
9
Impact of tirofiban on angiographic morphologic features of high-burden thrombus formation during direct percutaneous coronary intervention and short-term outcomes.替罗非班对直接经皮冠状动脉介入治疗期间高负荷血栓形成的血管造影形态学特征及短期预后的影响。
Chest. 2003 Sep;124(3):962-8. doi: 10.1378/chest.124.3.962.
10
Platelet-Lymphocyte ratio is a predictor for the development of no-reflow phenomenon in patients with ST-segment elevation myocardial infarction after thrombus aspiration.血小板-淋巴细胞比值是 ST 段抬高型心肌梗死患者血栓抽吸后无复流现象发展的预测因子。
J Clin Lab Anal. 2021 Jun;35(6):e23795. doi: 10.1002/jcla.23795. Epub 2021 May 4.

引用本文的文献

1
How an Aggressive Treatment of No-reflow Phenomenon in Primary Percutaneous Coronary Intervention with High Thrombus Burden can Achieve a Grade III TIMI-flow: A Case Report.高血栓负荷的原发性经皮冠状动脉介入治疗中对无复流现象进行积极治疗如何实现TIMI血流Ⅲ级:一例报告
Int J Angiol. 2023 Apr 10;34(3):233-237. doi: 10.1055/s-0043-1764475. eCollection 2025 Sep.
2
Clinical, laboratory, and procedural predictors of slow flow/no reflow phenomenon after emergency percutaneous coronary interventions in ST-elevated myocardial infarction.ST段抬高型心肌梗死患者急诊经皮冠状动脉介入治疗后慢血流/无复流现象的临床、实验室及操作预测因素
Egypt Heart J. 2024 Nov 4;76(1):146. doi: 10.1186/s43044-024-00577-0.
3
Utility of electrocardiogram to predict the occurrence of the no-reflow phenomenon in patients undergoing primary percutaneous coronary intervention (PPCI): a systematic review and meta-analysis.心电图预测接受直接经皮冠状动脉介入治疗(PPCI)患者无复流现象发生的效用:一项系统评价和荟萃分析。
Front Cardiovasc Med. 2024 Jan 8;10:1295964. doi: 10.3389/fcvm.2023.1295964. eCollection 2023.
4
The role and mechanisms of microvascular damage in the ischemic myocardium.微血管损伤在缺血性心肌中的作用和机制。
Cell Mol Life Sci. 2023 Oct 29;80(11):341. doi: 10.1007/s00018-023-04998-z.
5
Coronary Arteries Aneurysms: A Case-Based Literature Review.冠状动脉瘤:基于病例的文献综述。
Diagnostics (Basel). 2022 Oct 19;12(10):2534. doi: 10.3390/diagnostics12102534.
6
Predictive Value of Soluble Growth Stimulator Gene 2 Protein for Coronary Slow Flow/No-Reflow in ST-Elevation Myocardial Infarction Patients Receiving Percutaneous Coronary Intervention.可溶性生长刺激因子基因 2 蛋白对行经皮冠状动脉介入治疗的 ST 段抬高型心肌梗死患者冠状动脉慢血流/无复流的预测价值。
J Interv Cardiol. 2022 Apr 15;2022:9322460. doi: 10.1155/2022/9322460. eCollection 2022.
7
Autologous blood injection intracoronary artery for treating slow-flow and no-reflow in acute coronary syndrome related to primary pci.自体血冠状动脉内注射治疗与直接经皮冠状动脉介入治疗相关的急性冠状动脉综合征中的慢血流和无复流现象
Clin Case Rep. 2022 Feb 23;10(2):e05328. doi: 10.1002/ccr3.5328. eCollection 2022 Feb.
8
CHA2DS2 VASc score and brachial artery flow-mediated dilation as predictors for no-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.CHA2DS2-VASc评分和肱动脉血流介导的扩张作为接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者无复流现象的预测指标。
Egypt Heart J. 2022 Feb 23;74(1):13. doi: 10.1186/s43044-022-00249-x.
9
Stenting deferral in primary percutaneous coronary intervention: exploring benefits and suitable interval in heavy thrombus burden.在直接经皮冠状动脉介入治疗中延迟支架置入:探讨在血栓负荷较重情况下的益处及合适的间隔时间。
Egypt Heart J. 2021 Sep 9;73(1):78. doi: 10.1186/s43044-021-00203-3.
10
Coronary microvascular injury in myocardial infarction: perception and knowledge for mitochondrial quality control.心肌梗死中的冠状动脉微血管损伤:对线粒体质量控制的认识和了解。
Theranostics. 2021 May 3;11(14):6766-6785. doi: 10.7150/thno.60143. eCollection 2021.

本文引用的文献

1
The SYNTAX Score Can Predict Major Adverse Cardiac Events Following Percutaneous Coronary Intervention.SYNTAX评分可预测经皮冠状动脉介入治疗后的主要不良心脏事件。
Heart Views. 2014 Oct-Dec;15(4):99-105. doi: 10.4103/1995-705X.151081.
2
In-hospital and 12-month outcomes after acute coronary syndrome treatment in patients aged<40 years of age (from the Polish Registry of Acute Coronary Syndromes).急性冠状动脉综合征患者<40 岁时的住院期间和 12 个月的结局(来自波兰急性冠状动脉综合征注册研究)。
Am J Cardiol. 2014 Jul 15;114(2):175-80. doi: 10.1016/j.amjcard.2014.04.024. Epub 2014 May 2.
3
Predictors of thrombus burden and no-reflow of infarct-related artery in patients with ST-segment elevation myocardial infarction: importance of platelet indices.ST段抬高型心肌梗死患者梗死相关动脉血栓负荷及无复流的预测因素:血小板指标的重要性
Blood Coagul Fibrinolysis. 2014 Oct;25(7):709-15. doi: 10.1097/MBC.0000000000000130.
4
Effect of pre-procedural statin therapy on myocardial no-reflow following percutaneous coronary intervention: a meta analysis.术前他汀类药物治疗对经皮冠状动脉介入治疗后心肌无复流的影响:荟萃分析。
Chin Med J (Engl). 2013;126(9):1755-60.
5
SYNTAX score is a predictor of angiographic no-reflow in patients with ST-elevation myocardial infarction treated with a primary percutaneous coronary intervention.SYNTAX评分是接受直接经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者血管造影无复流的预测指标。
Coron Artery Dis. 2013 Mar;24(2):148-53. doi: 10.1097/MCA.0b013e32835c4719.
6
Incidence and outcomes of no-reflow phenomenon during percutaneous coronary intervention among patients with acute myocardial infarction.急性心肌梗死患者经皮冠状动脉介入治疗中无复流现象的发生率及转归。
Am J Cardiol. 2013 Jan 15;111(2):178-84. doi: 10.1016/j.amjcard.2012.09.015. Epub 2012 Oct 27.
7
Usefulness of the SYNTAX score to predict "no reflow" in patients treated with primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.SYNTAX 评分预测 ST 段抬高型心肌梗死患者行直接经皮冠状动脉介入治疗后无复流的价值。
Am J Cardiol. 2012 Mar 1;109(5):601-6. doi: 10.1016/j.amjcard.2011.10.013. Epub 2011 Dec 15.
8
Usefulness of transient and persistent no reflow to predict adverse clinical outcomes following percutaneous coronary intervention.经皮冠状动脉介入治疗后无复流的一过性和持续性对不良临床结局的预测价值。
Am J Cardiol. 2012 Feb 15;109(4):478-85. doi: 10.1016/j.amjcard.2011.09.037. Epub 2011 Dec 15.
9
Independent no-reflow predictors in female patients with ST-elevation acute myocardial infarction treated with primary percutaneous coronary intervention.接受直接经皮冠状动脉介入治疗的ST段抬高型急性心肌梗死女性患者的无复流独立预测因素。
Heart Vessels. 2012 May;27(3):243-9. doi: 10.1007/s00380-011-0144-2. Epub 2011 Apr 28.
10
Angiographic thrombus burden classification in patients with ST-segment elevation myocardial infarction treated with percutaneous coronary intervention.接受经皮冠状动脉介入治疗的ST段抬高型心肌梗死患者的血管造影血栓负荷分类
J Invasive Cardiol. 2010 Oct;22(10 Suppl B):6B-14B.

接受直接经皮冠状动脉介入治疗患者中“无复流”或“慢血流”现象的相关因素

Correlates of the "No-Reflow" or "Slow-Flow" Phenomenon in Patients Undergoing Primary Percutaneous Coronary Intervention.

作者信息

Alidoosti Mohammad, Lotfi Reza, Lotfi-Tokaldany Masoumeh, Nematipour Ebrahim, Salarifar Mojtaba, Poorhosseini Hamidreza, Jalali Arash

机构信息

Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran.

出版信息

J Tehran Heart Cent. 2018 Jul;13(3):108-114.

PMID:30745923
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6368911/
Abstract

Despite recent advances in interventional equipment and techniques, the angiographic no-reflow phenomenon occurs in a considerable number of patients undergoing primary percutaneous coronary intervention (PCI). We investigated the clinical, angiographic, preprocedural, and procedural characteristics associated with the no-reflow phenomenon among patients undergoing primary PCI. Between March 2008 and April 2013, 530 patients (78.5% male, mean age=58.11±12.39 y) with ST-segment-elevation myocardial-infarction who underwent primary PCI were categorized in 2 groups according to their postprocedural thrombolysis-in-myocardial infarction (TIMI) flow grades: those with a maximum score of 2 (the no-reflow or slow-flow group) and the ones with a score of 3 (the reflow group). A multivariable logistic regression model was used to find the multiple correlates of the no-reflow phenomenon after PCI. There were 166 (31.3%) patients in the no-reflow group and 364 (68.7%) in the reflow group. The no-reflow patients were older and had significantly longer target lesion lengths, higher SYNergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) scores, higher infarct-related artery SYNTAX scores, more thrombus burden, and a higher frequency of initial TIMI flow grades of 2 or lower. Our multivariable logistic regression analysis demonstrated that older age, higher numbers of Q waves, not using statin, longer target lesion lengths, higher thrombus grades, and higher infarct-related artery SYNTAX scores remained the independent correlates of increased no-reflow rates after primary PCI (area under the ROC curve=0.784, 95% CI: 0.742-0.826; P<0.001). Clinical, angiographic, and procedural features of patients undergoing primary PCI may be correlated with the occurrence of the no-reflow phenomenon. The thrombus grade and the infarct-related artery SYNTAX score could be among these factors.

摘要

尽管介入设备和技术最近取得了进展,但相当多接受直接经皮冠状动脉介入治疗(PCI)的患者会出现血管造影无复流现象。我们调查了接受直接PCI的患者中与无复流现象相关的临床、血管造影、术前和术中特征。在2008年3月至2013年4月期间,530例接受直接PCI的ST段抬高型心肌梗死患者(78.5%为男性,平均年龄=58.11±12.39岁)根据术后心肌梗死溶栓(TIMI)血流分级分为两组:最高评分为2分的患者(无复流或慢血流组)和评分为3分的患者(复流组)。采用多变量逻辑回归模型来寻找PCI术后无复流现象的多个相关因素。无复流组有166例(31.3%)患者,复流组有364例(68.7%)患者。无复流患者年龄较大,靶病变长度明显更长,经皮冠状动脉介入治疗与心脏手术协同作用(SYNTAX)评分更高,梗死相关动脉SYNTAX评分更高,血栓负荷更大,初始TIMI血流分级为2级或更低的频率更高。我们的多变量逻辑回归分析表明,年龄较大、Q波数量较多、未使用他汀类药物、靶病变长度较长、血栓分级较高以及梗死相关动脉SYNTAX评分较高仍然是直接PCI后无复流率增加的独立相关因素(ROC曲线下面积=0.784,95%CI:0.742-0.826;P<0.001)。接受直接PCI的患者的临床、血管造影和术中特征可能与无复流现象的发生相关。血栓分级和梗死相关动脉SYNTAX评分可能是这些因素之一。